Replimune Group, Inc. (REPL)
Free
No email, no account, no signup.
Pulling latest news for Replimune Group, Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Oncolytic immunotherapies
Market Cap
$390M
We're already tracking Replimune Group, Inc. — here are the latest events we've registered
Recent News
- In May 2026, Replimune received a Complete Response Letter from the FDA rejecting its Biologics License Application for RP1 in advanced melanoma. The stock subsequently experienced high volatility following reports of potential leadership changes at the FDA that could impact the drug's regulatory path. CEO Sushil Patel expressed disappointment with the decision and indicated that the company is evaluating the viability of the RP1 program.
Want to know how this news affects Replimune Group, Inc.? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Replimune Group, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.